<DOC>
	<DOCNO>NCT00949117</DOCNO>
	<brief_summary>RATIONALE : Cyproheptadine hydrochloride may help improve appetite lessen weight loss cause cancer cancer treatment . It yet know whether cyproheptadine hydrochloride effective without nutritional supplementation improve weight quality life young patient weight loss cause cancer cancer treatment . PURPOSE : This randomized phase II trial study cyproheptadine hydrochloride see well work give together without nutritional supplementation treat young patient weight loss cause cancer cancer treatment .</brief_summary>
	<brief_title>Cyproheptadine Hydrochloride Nutritional Supplementation Treating Young Patients With Weight Loss With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare efficacy appetite stimulant , cyproheptadine hydrochloride , v without nutritional supplement , PediaSure Ensure , improve weight extend duration response pediatric patient cancer- cancer treatment-related weight loss . Secondary - To compare pattern body composition weight change patient treat regimen . - To compare change relationship pre-albumin ( biomarker malnutrition ) weight improvement baseline completion study treatment . - To compare change quality life measure Pediatric Functional Assessment Anorexia Cachexia Therapy ( FAACT ) questionnaire patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord participate center steroid use ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral cyproheptadine hydrochloride twice daily 24 week absence weight loss unacceptable toxicity . - Arm II : Patients receive oral cyproheptadine hydrochloride twice daily oral PediaSure ( 2 10 year age ) Ensure ( &gt; 10 year age ) twice daily 24 week absence weight loss unacceptable toxicity . Patients undergo blood sample collection ass pre-albumin level baseline week 4 24 . Patients also undergo assessment body composition , lean body mass , percentage body fat baseline week 4 24 assessment weight height baseline week 4 , 8 , 12 , 16 , 20 , 24 . Patients also complete food diary twice week study treatment . Patients 7-17 year age complete quality-of-life questionnaire baseline week 4 24 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Body Weight Changes</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>INCLUSION CRITERIA : â‰¥ 2 year &lt; 18 year age time admission study Meets one follow criterion : document history unintended weight loss &gt; 5 % presumed secondary cancer/treatmentrelated therapy within three month BMI age le 5th percentile Diagnosed cancer type Concomitant cancer treatment ( surgery , chemotherapy , radiotherapy ) guideline : Patients complete concomitant cancer treatment study 's 4week intervention eligible If patient receive concomitant cancer treatment , schedule get least another 4 week treatment order reach primary endpoint If patient already complete cancer treatment , need enrol within 8 week complete therapy . Predicted life expectancy least 6 month EXCLUSION CRITERIA : Currently take study agent ( cyproheptadine hydrochloride ( CH ) , PediaSure , Ensure ) take study agent past 3 week History anorexia nervosa bulimia Initiation appetite enhance agent include steroid prescribe intent weight gain , i.e . Megace , allow study Children receive steroid part daily cancer treatment regimen exclude participation . However , intermittent steroid use antiemetic regimen pulse steroid therapy allow study . Use forms nutrition therapy , e.g . total parenteral nutrition ( TPN ) enteral tube feeding within 3 week study entry study Receiving monoamine oxidase ( MAO ) inhibitor , procarbazine , fluoxetine ( SSRI ) , paroxetine ( SSRI ) Taking dronabinol ( Marinol ) appetitestimulating medication past 3 week Diagnosed glaucoma , cystic fibrosis , inflammatory bowel disease GI genitourinary ( GU ) obstruction Allergy study agent Hypersensitivity specific milk protein Pregnant lactating . Females childbearing potential require use effective contraception study agent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>malnutrition</keyword>
	<keyword>weight change</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia</keyword>
	<keyword>myeloid malignancy</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage I childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage II childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>